Direct-to-brain Chemo Better Than Systemic Drugs When Immunotherapy is to Follow
Animal study suggests “best practice” for preserving the immune system
In experiments on mice with a form of aggressive brain cancer, Johns Hopkins researchers have shown that localized chemotherapy delivered directly to the brain rather than given systemically may be the best way to keep the immune system intact and strong when immunotherapy is also part of the treatment. The researchers say their study results could directly affect the design of immunotherapy clinical trials and treatment strategies for people with a deadly form of brain cancer call glioblastoma. “We understand that our research was done in a mouse model and not in humans, but our evidence is strong that systemic chemotherapy alters the immune system in a way that it never fully recovers,” says Michael Lim, MD, associate professor of neurosurgery and director of brain tumor immunotherapy at the Johns Hopkins Kimmel Cancer Center. “With aggressive cancers like glioblastoma, it is important that we don’t handicap the defenses we may need to add alternative treatments, such as immunotherapy, to chemotherapy,” he adds.
Click here to read more.
2017 National Neuroscience Review
March 31-April 1, 2017; National Harbor, Md.
Brain & Brain PET 2017
April 1-4, 2017; Berlin, Germany
Neurosurgical Society of America Annual Meeting 2017
April 2-5, 2017; Jacksonville, Fla.
13th Head & Neck Cancer Symposium
April 6-7, 2017; Amsterdam, The Netherlands
Endoscopic and Endoscope-Assisted Neurosurgery Under FULL HD Visualization
April 6-7, 2017; Germany
Be the first to reply using the above form.